In the last trading session, 1.72 million shares of the Summit Therapeutics Inc (NASDAQ:SMMT) were traded, and its beta was -0.53. Most recently the company’s share price was $20.24, and it changed around -$0.45 or -2.17% from the last close, which brings the market valuation of the company to $14.93B. SMMT currently trades at a discount to its 52-week high of $33.89, offering almost -67.44% off that amount. The share price’s 52-week low was $2.10, which indicates that the current value has risen by an impressive 89.62% since then. We note from Summit Therapeutics Inc’s average daily trading volume that its 10-day average is 2.18 million shares, with the 3-month average coming to 2.43 million.
Summit Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended SMMT as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Summit Therapeutics Inc is expected to report earnings per share of -0.07 for the current quarter.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Instantly SMMT has showed a red trend with a performance of -2.17% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 20.82 on recent trading dayincreased the stock’s daily price by 2.79%. The company’s shares are currently up 13.42% year-to-date, but still up 2.07% over the last five days. On the other hand, Summit Therapeutics Inc (NASDAQ:SMMT) is 7.43% up in the 30-day period. We can see from the shorts that 21.63 million shares have been sold at a short interest cover period of 9.05 day(s).
The consensus price target as assigned by Wall Street analysts is $37, which translates to bulls needing to increase their stock price by 45.3% from its current value. Analyst projections state that SMMT is forecast to be at a low of $32 and a high of $42.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -10.52%. Summit Therapeutics Inc earnings are expected to increase by -39.43% in 2025, but the outlook is negative -28.40% per year for the next five years.
SMMT Dividends
Summit Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-23.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 84.36% of Summit Therapeutics Inc shares, and 12.91% of them are in the hands of institutional investors. The stock currently has a share float of 82.60%. Summit Therapeutics Inc stock is held by 273.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 3.2804% of the shares, which is about 23.22 million shares worth $181.13 million.
VANGUARD GROUP INC, with 1.2566% or 8.82 million shares worth $68.78 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR(R) S&P(R) Biotech ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.4 shares worth $68.91 million, making up 0.46% of all outstanding shares. On the other hand, SPDR(R) S&P(R) Biotech ETF held roughly 3.32 shares worth around $67.21 million, which represents about 0.45% of the total shares outstanding.
